Member Info for inanaco

Covid delivery system ...

Nottingham Trent University showcases plant nutrient technology at Edible Garden Show
A groundbreaking development in the formulation of natural nanoparticle plant nutrients was showcased at the Edible Garden Show (March 11-13) by scientists from Nottingham Trent University.

A groundbreaking development in the formulation of natural nanoparticle plant nutrients was showcased at the Edible Garden Show (March 11-13) by scientists from Nottingham Trent University. An R&D initiative was announced at the show for the development of a nano-fertiliser range developed in conjunction with Lorbex, the specialist garden products business.

Trials of the formulations on tomatoes, chillies and a broad range of other plants have shown up to 90% additional yield when compared to NPK fertiliser containing a full range of trace elements.

The most significant application for this technology is for the agricultural and pharmaceutical market, but through the university's research and development collaboration with Lorbex, this technology can support a range of nutrient-enhanced feeds suitable for the consumer market.

https://www.ntu.ac.uk/about-us/news/news-articles/2016/03/nottingham-trent-university-showcases-plant-nutrient-technology-at-edible-garden-show

https://uk.finance.yahoo.com/quote/SCLP.L?p=SCLP.L&.tsrc=fin-srch

the little blip before the main rise ...

back in 2012 we had this sticky point at 12p .... it lasted days ... then took of again and crept up to 19p before the big RNS moditope

history repeating

A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates
Annette Vogel, Isis Kanevsky, Ye Che, Kena Swanson, Alexander Muik, Mathias Vormehr, Lena Kranz, Kerstin Walzer, Stephanie Hein, Alptekin Gueler, Jakob Loschko, Mohan Maddur, Kristin Tompkins, Journey Cole, Bonny Gaby Lui, Thomas Ziegenhals, Arianne Plaschke, David Eisel, Sarah Dany, Stephanie Fesser, Stephanie Erbar, ferdia Bates, Diana Schneider, Bernadette Jesionek, Bianca Saenger, Ann-Kathrin Wallisch, Yvonne Feuchter, Hanna Junginger, Stefanie Krumm, Andre Heinen, Petra Adams-Quack, Julia Schlereth, Christoph Kroener, Shannan Hall-Ursone, Kathleen Brasky, Matthew C Griffor, Seungil Han, Joshua Lees, Ellene Mashalidis, Parag Sahasrabudhe, Charles Tan, Danka Pavliakova, Guy Singh, Camila Fontes-Garfias, Michael Pride, Ingrid Scully, tara Ciolino, Jennifer Obregon, Michal Gazi, Ricardo Carrion, Kendra Alfson, Warren Kalina, Deepak Kaushal, Pei-Yong Shi, Thorsten Klamp, Corinna Rosenbaum, Andreas Kuhn, Oezlem Tuereci, Philip Dormitzer, Kathrin Jansen, Ugur Sahin
bioRxiv 2020.09.08.280818; doi: https://doi.org/10.1101/2020.09.08.280818

To contain the coronavirus disease 2019 (COVID-19) pandemic, a safe and effective vaccine against the new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is urgently needed in quantities sufficient to immunise large populations. In this study, we report the design, preclinical development, immunogenicity and anti-viral protective effect in rhesus macaques of the BNT162b2 vaccine candidate. BNT162b2 contains an LNP-formulated nucleoside-modified mRNA that encodes the spike glycoprotein captured in its prefusion conformation. After expression of the BNT162b2 coding sequence in cells, approximately 20% of the spike molecules are in the one-RBD up, two-RBD down state. Immunisation of mice with a single dose of BNT162b2 induced dose level-dependent increases in pseudovirus neutralisation titers. Prime-boost vaccination of rhesus macaques elicited authentic SARS-CoV-2 neutralising geometric mean titers 10.2 to 18.0 times that of a SARS-CoV-2 convalescent human serum panel. BNT162b2 generated strong TH1 type CD4+ and IFNy+ CD8+ T-cell responses in mice and rhesus macaques. The BNT162b2 vaccine candidate fully protected the lungs of immunised rhesus macaques from infectious SARS-CoV-2 challenge. BNT162b2 is currently being evaluated in a global, pivotal Phase 2/3 trial (NCT04368728).

Fantastic ....... that is what i wanted to hear ...... Skin in the game is not just about financial .. i am here because the science challenged me .. I don't need the money however its a by product of what i do .. any way great post ... and Thanks for confirming that what has been presented by Scancell could have serious potential as we move forward through the trials .. etc ... I am afraid Ruck will always try to undermine and wreck any attempt to get quality threads generated .. read his history

thing is Burble ....... do you have skin in the Game ... ?

at the end of the day are you backing SCIB1 ... or questioning it from the data already presented by the trial results and scientific papers

past posts i have done has covered

loss of MHC 1 and 11 expression

apparently i have duped people .......

"""" There were no clinically significant changes in laboratory
values during the study that were associated with SCIB1 administration (data not shown). """

if you actually read the trial data ........... the entire repertoire of test that one has .... shows NO change

which is why Scancell is targeting 55% ............ not 100%

For a start ........ SCib1 has induced T cells That secrete IFny and they can detect that specific signature and in patients with solid Tumor present. Proven

nobody has yet died from SCIB1 however one patient dropped out because it made his arm sore

... however he will die from the cancer ... they will also die from keytruda !!

KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended.

sometimes explaining the DIRE warnings ... really is a bit over kill

Glitch ..... its not the thought police

the site has issues .......... threads disappear regardless of content

judging by the after hours trading ... Scancell shares are still in high demand, and if you look at market cap v what we are doing, you can see why ...

mine is chimeric ...... sweetex

the glycan is a sugar its the target ......... our Mabs go for that target

Its an exciting time ........... i would rather spend it predicting the outcome of the science .... and back my hunch .

than making all sorts of waffle about risk that those blabbering about it don't have a clue how to evaluate it ..

i do not see any synergy between Keytruda and the Glycans ... in fact the Clycans completely bypass the cancers Clocking device because they are MABs not T cells ... the possibility is the Clycans can spark an innate immune response as well .... via PAMPs ..

chimeric is a mutant ....
Humanised is human .....

Immunobody mark 1 and 2 ...

https://www.genengnews.com/topics/drug-discovery/scancell-gains-rights-to-mab-from-crt-for-immunotherapy-development/

point i am making Scancell scib1 has TIL ... able to take on solid tumor indeed has made lesions disappear on the lung ...

so we know that SCIB1 t cells work

Keytruda acts only on the T cells .. no other influence, which is why off target toxicity manifests ... as all T cells are its target

SCIB1 has shown no off target toxicity ..... that we are aware off ...